Orion Oyj

Orion Oyj

ORINY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$31.98B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Orion OyjOrion Oyj221.75%47%18.90.1

Earnings Call Q3 2026

October 28, 2026 - AI Summary

Strong Q3 + upgraded full-year outlook (good execution) - Net sales: +28% YoY to EUR 542m - Operating profit: ~+74% YoY to EUR 210m - EPS: grew “accordingly” (no exact figure provided in transcript) - YTD (Jan–Sep): Net sales +24% to EUR 1.481bn; Operating profit +~66% to >EUR 500m - Guidance upgrade (full year 2026): - Net sales: EUR 2.070bn–2.140bn (upgraded) - Operating profit: EUR 730m–790m (upgraded)
Nubeqa remains the earnings engine; biggest driver and biggest uncertainty (opportunity + risk) - Nubeqa drives Q3 growth: +EUR 113m in net sales from Innovative Medicines; ~70% growth in “Top 10 products” table. - Q3 mix/growth mechanics: company is already at maximum Nubeqa royalty tier since Q2, so royalties should scale ~proportionally with Bayer’s market sales. - Guidance still has a wide Q4 range largely due to Nubeqa: Q4 is expected to be one of the best quarters for Nubeqa (fast-growing product + maximum royalty rate), but variability remains. - Softness vs consensus in Q3 royalties (potentially a negative/surprise): management said discrepancies can come from timing/estimation of Bayer sales and how the “last month” is booked—they did not give a concrete operational cause.
Commercial update: royalties vs tablet sales—some variability but not alarming - Royalties & Bayer reporting: Q3 royalties EUR 222m, plus tablet sales EUR 58m to Bayer (as described). - Tablet sales sequential decline noted by an investor (~10%); management response: likely normal quarter-to-quarter shipment batching/maintenance break effects, not a fundamental demand issue. - Overall messaging: trend is upward over the year, even if quarter shipments swing.

Exclusive for Stockcircle Pro members

Sign upSign Up
$21.58

Current Fair Value

62% downside

Overvalued by 62% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$31.98 Billion
Enterprise Value$32.01 Billion
Annual dividend$1.02
Dividend yield1.75%
Earnings per Share$0.86
Beta0.29
Outstanding Shares563,361,344

Return

Return on Equity47.10%ROE
Return on Assets32.39%
Return on Invested Capital53.79%

Valuation & Multiples

P/E Ratio22.01P/E Ratio
PEG29.51PEG
Price to Sales18.92Price to Sales
Price to Book Ratio28.39Price to Book Ratio
Enterprise Value to Revenue14.7
Enterprise Value to EBIT38.58
Enterprise Value to Net Income48
Total Debt to Enterprise0.01
Debt to Equity0.12Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 28, 2026
EPS
$0.68
Reported
Revenue
$605.65 M
Est. $604.66 M

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Orion Oyj

4,029 employees
CEO: Aino Anna Liisa Hurme

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are sp...